Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients

Study Overview
=================
Brief Summary
-----------------
First, the investigators examined the functional relevance of serotonin transporter polymorphisms by quantifying the activity of serotonin transporter in blood platelets of genotyped healthy volunteers and patients with major depression. Second, the investigators studied response to SSRIs in relation to 5-HTTLPR genotype and also to the functional expression of 5-HTT in platelets.

Detailed Description
-----------------
The purpose of this study is to determine whether serotonin transporter genotypic or functional differences between depressive patients and normal controls were existed. to determine the relationship between serotonin transporter polymorphisms and serotonin transporter functional expression. to determine whether genomic or functional differences between drug responders and nonresponders predict the response of antidepressant

Official Title
-----------------
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients

Conditions
-----------------
Depression, Continuous Antidepressant Abuse, Adverse Reaction to Drug

Intervention / Treatment
-----------------
* Drug: SSRI treated group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians Exclusion Criteria: received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SSRI treated group<br>SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline | Drug: SSRI treated group<br>* characterize in arm of a study (SSRI treated group)<br>* Other names: sertraline_Zoloft;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antidepressant Response at 2,4,6 weeks |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biological value at 0 and 6 weeks |  | 6weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacogenomics, Prediction of Antidepressant Response, Depressed Patients